This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- It's nice to see the flow of money has reversed from last week's relentless selloff, Jim Cramer told his Mad Money viewers Monday. In fact, there were two reasons the markets were able to rally -- a positive news flow and money managers looking to add more stocks to their portfolios.

There were a number of positive headlines driving the markets, including a wave of mergers in the biotech sectors. Horizon Pharmaceuticals (HZNP) was one notable deal and its stock up a quick 18%. Teva Pharmaceuticals (TEVA) was also up on the day, as was Catamaran (CTRX), up 27%.

Must Read: Warren Buffett's Top 10 Stock Buys

There were also several positive research reports helping to vault stocks higher. An upgrade of Analog Devices (ADI) made Cramer re-recommend Skyworks Solutions (SWKS), while upgrades of Restoration Hardware (RH) and Nike (NKE) also caught his eye.

In addition to all this positive stock news, it's also apparent that mutual funds are once again buying after last week's exodus. Funds are calmly looking for more exposure to stocks now that this most challenging quarter is coming to an end.

Buy, Buy, Buy Harris

With the news that Harris (HRS - Get Report) is buying Excelis (XLS), are shares still worth buying? According to Cramer, absolutely.

Harris is already a strong defense contractor providing secure radio frequency communications and encryption systems for government and military use. By adding Excelis to the mix, the combined company will also be able to offer night vision and radar reconnaissance products, all while saving an estimated $120 million a year.

Shares of Excelis are up 57% since Cramer first recommended them in November 2013, and he sees no reason to change his view now. The new Harris will have tons of room to grow overseas and currently trades at just 15 times earnings, as discount to its peers.

The new Harris also brings a solid management team that will easily be able to transform the combined company into a top 10 defense contractor, sending shares much higher.

Must Read: Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
HRS $77.63 0.00%
LULU $64.83 0.00%
AAPL $125.80 -0.45%
FB $83.20 0.00%
GOOG $552.03 0.00%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs